Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
The advent of new disease-modifying therapies (DMTs), such as monoclonal antibodies (mAbs), resulted in significant changes in the treatment guidelines for Multiple sclerosis (MS) and improvement in the clinic...
Source: BMC Health Services Research - Category: General Medicine Authors: Mansour A. Alharbi, Fahad Aldosari, Ahmed Hasan Althobaiti, Faris M. Abdullah, Salman Aljarallah, Nuha M. Alkhawajah, Miteb Alanazi and Yazed AlRuthia Tags: Research Source Type: research
More News: General Medicine | Middle East Health | Multiple Sclerosis | Rituxan | Saudi Arabia Health | Tysabri